

Evaluating The Impact Of Opioid Prescribing Practices On Public Health And Overdose Rates In The United States: A Case Study Of Maryland

Audu Rebecca Simbiat¹

¹(Healthcare Management, American National University, United State Of America)

Abstract:

Background: This study examines the impact of opioid prescribing practices on overdose rates and public health outcomes in Maryland. The opioid crisis has escalated, with rising overdose rates despite interventions aimed at reducing opioid misuse. Maryland has introduced several regulatory measures, such as the Prescription Drug Monitoring Program (PDMP) and stricter prescribing guidelines, to address this issue.

Materials and Methods: Using document analysis, we reviewed Maryland's opioid prescribing regulations, including the PDMP and stricter prescribing guidelines, alongside overdose statistics from 2010 to 2020. This methodology allowed us to evaluate the effectiveness of these policies in reducing opioid-related overdose deaths in Maryland.

Results: Key findings reveal that while opioid prescriptions decreased significantly following the introduction of these regulations, overdose rates continued to rise, primarily driven by the increasing prevalence of fentanyl. In particular, fentanyl-related fatalities surged, accounting for 70% of all opioid-related deaths by 2020. The data also highlighted significant geographical and demographic disparities, with urban and socio-economically disadvantaged areas being most affected.

Conclusion: These findings suggest that while prescription controls have reduced opioid misuse, they have not fully addressed the broader opioid crisis, especially the rise of illicit opioids like fentanyl. The study emphasizes the need for a more comprehensive public health approach that integrates stricter monitoring, expanded addiction treatment, harm reduction strategies, and targeted interventions for at-risk populations. This research underscores the importance of balancing prescription regulation with efforts to tackle the growing prevalence of illicit opioid use to effectively curb overdose deaths.

Key Word: Opioid prescribing, overdose rates, fentanyl, public health, regulations, PDMP.

Date of Submission: 02-05-2025

Date of Acceptance: 12-05-2025

I. Introduction

The opioid crisis in the United States has evolved into one of the most pressing public health emergencies of the 21st century. According to the Centers for Disease Control and Prevention (2024), opioid overdose deaths have been steadily rising for over two decades, with opioids now responsible for a significant portion of all drug-related fatalities. In 2020 alone, there were over 91,000 drug overdose deaths, with opioids accounting for more than 69% of these fatalities[1]. It has been highlighted that this crisis has affected nearly every state, but its impact has been especially severe in Maryland, where overdose deaths have surged dramatically in recent years[2]. Maryland saw a record number of overdose deaths in 2020, with opioids, particularly fentanyl, contributing to a large proportion of these deaths[3].

The issue of opioid misuse in Maryland is compounded by a complex mix of socioeconomic factors, regional disparities, and healthcare practices[4]. Maryland, like many states, has faced challenges in balancing the need for appropriate pain management with the risk of over-prescribing opioids, which has led to both widespread addiction and an increase in overdose deaths[5]. In response, public health officials and policymakers have increasingly focused on addressing opioid prescribing practices as a primary avenue for reducing the harm caused by these substances[6].

Historically, the medical community relied on opioids as a standard treatment for pain management, leading to an escalation in prescriptions over the years[7]. However, the increase in opioid prescriptions has been paralleled by a rise in misuse and overdose rates, as well as the development of opioid use disorder [8]. It has been emphasized that the introduction of prescription drug monitoring programs (PDMPs) and revised prescribing guidelines over the past decade reflect an effort to mitigate the crisis by controlling prescription practices [9]. Despite these efforts, the effects of opioid prescribing on public health outcomes, especially overdose rates, remain a critical concern[10].

II. Material And Methods

This study employs a secondary research methodology, utilizing document analysis to assess the impact of opioid prescribing regulations on overdose rates and public health outcomes in Maryland. The purpose of this methodology is to examine the connections between regulatory changes and overdose trends over time, specifically focusing on the influence of the Prescription Drug Monitoring Program (PDMP) and other opioid prescribing regulations. The research analyzes various data sources, including state-level public health reports, overdose statistics, and relevant policy documents, to gain insights into how changes in opioid prescribing practices have affected the opioid crisis in Maryland.

Study Design: Secondary research design using document analysis.

Study Location: The study is based in the state of Maryland, which has been heavily impacted by the opioid epidemic. Maryland's response to this crisis has included several regulatory measures, including the introduction of the Prescription Drug Monitoring Program (PDMP) and updated prescribing guidelines. These efforts provide a unique opportunity to assess the effectiveness of opioid prescribing regulations within a real-world context.

Study Duration: The study spans a period from 2010 to 2020, capturing the significant regulatory changes implemented in Maryland, alongside opioid-related overdose statistics. This timeline allows for a thorough examination of the trends in opioid prescribing and overdose fatalities before and after key regulatory interventions.

Sample size: This study does not require a traditional sample size calculation, as it involves document and data analysis rather than a sample of individuals. The analysis will utilize publicly available documents, such as Maryland Department of Health reports and national statistics, which offer comprehensive data on opioid prescriptions and overdose deaths.

Subjects & selection method: The study involves the review of secondary data from public health reports and state legislation. The primary data sources for analysis include the Maryland Department of Health's overdose death reports, prescription rates, and the state's opioid prescribing laws. No specific subjects or individuals are selected for this study, as it is based on aggregate data collected from governmental and health-related sources.

Inclusion criteria:

The documents included in this study consist of publicly available records from Maryland's opioid-related legislation, regulatory guidelines (such as the PDMP), and overdose statistics from 2010 to 2020. Data from both state and federal health agencies, such as the CDC, are also included as they provide an important comparative context for Maryland's opioid crisis.

Exclusion criteria:

This study excludes non-governmental data sources that may lack reliability or comprehensive statewide representation. It also excludes data that is incomplete or does not provide clear links between opioid prescribing regulations and overdose statistics within the study period. Additionally, personal case studies or anecdotal evidence that do not reflect broad trends in Maryland's public health efforts are not considered in the analysis.

Procedure methodology

This study follows a secondary research design, utilizing document analysis to evaluate the impact of opioid prescribing regulations on overdose rates and public health outcomes in Maryland. The process begins by identifying and gathering key documents, including Maryland's opioid prescribing regulations, Prescription Drug Monitoring Program (PDMP) reports, and public health statistics from 2010 to 2020. Relevant documents are sourced from the Maryland Department of Health, the Centers for Disease Control and Prevention (CDC), and other public health entities. These documents provide data on opioid prescriptions, overdose rates, and regulatory changes, such as the introduction of the PDMP in 2011 and stricter prescribing guidelines in 2017.

Once the data is collected, it will be organized and analyzed to examine trends in opioid prescriptions, overdose statistics, and the effectiveness of the regulations. The primary goal is to assess whether the implementation of the PDMP and updated prescribing guidelines led to reductions in opioid prescriptions and overdose deaths. The analysis also includes reviewing demographic and geographical disparities, and identifying which communities and regions were most affected by the opioid crisis. Special attention will be paid to the increasing role of fentanyl in driving overdose deaths, particularly as fentanyl-related fatalities have surged in recent years.

By comparing pre- and post-regulation data, this study aims to establish whether regulatory measures had a measurable impact on overdose rates and opioid misuse. The analysis will provide a comprehensive understanding of how changes in prescribing practices, public health policies, and the rise of illicit substances like fentanyl have interacted to shape Maryland’s opioid crisis.

Statistical analysis

The analysis will use a comparative approach, examining opioid-related data before and after key regulatory interventions. The primary goal is to assess whether the reduction in opioid prescriptions, driven by the PDMP and stricter prescribing guidelines, corresponds with a decrease in overdose deaths. Additionally, the study will analyze demographic and geographical disparities, highlighting which populations and regions are most affected by the crisis. Special attention will be paid to the increasing role of fentanyl in opioid overdoses, as its rise has complicated the impact of prescription controls. Statistical data will be compared to identify correlations between regulatory changes and overdose trends, while qualitative analysis will provide context on the broader public health implications of these findings. The final analysis aims to offer insights into the effectiveness of Maryland’s opioid prescribing policies and suggest improvements for addressing the broader opioid crisis.

III. Result

The document analysis and data collected revealed several important insights regarding opioid prescribing practices and overdose trends in Maryland. The key findings show a correlation between changes in opioid prescribing policies and a shift in the nature of overdose fatalities. Specifically, while opioid prescribing regulations, such as the Prescription Drug Monitoring Program (PDMP) and stricter prescribing guidelines, have reduced opioid prescriptions, they have not led to a corresponding decrease in overdose deaths. This is primarily due to the increased prevalence of fentanyl, a synthetic opioid, which has contributed to a sharp rise in overdose fatalities.

The data presented below highlights both the regulatory changes and the overdose statistics, serving as the foundation for the subsequent analysis of their relationship.

Data Presentation

1. Opioid Prescribing Data in Maryland

The following table presents the data related to opioid prescriptions and the regulatory measures enacted to control opioid prescribing in Maryland:

Data Point	Value	Source
Opioid Prescriptions (2010–2016)	25% decrease in opioid prescriptions state-wide	Maryland Department of Health, Prescription Drug Monitoring Program Report, 2016[11]
High-Volume Prescriber Reduction (2011–2016)	18% reduction in high-volume opioid prescribers	Maryland Department of Health, Prescription Drug Monitoring Program Report, 2016[11]
Opioid Prescription Rate per 100 Residents (2011–2016)	63 prescriptions per 100 residents in 2011; 48 in 2016	Maryland Department of Health, Prescription Drug Monitoring Program Report, 2016[11]
Opioid Prescription Rate per 100 Residents (2019–2023)	42.4 prescriptions per 100 residents in 2019; 51.7 in 2016	Opioid Dispensing Rate Maps, Maryland, 2024[12]
Stricter Prescribing Guidelines Impact (2017)	12.42% reduction in opioid prescriptions in 2017	Maryland Health Care Commission, 2018[13]

This table provides insight into Maryland's efforts to regulate opioid prescribing. Following the introduction of the Prescription Drug Monitoring Program (PDMP) in 2011 and stricter opioid prescribing guidelines in 2017, the state saw a notable reduction in the number of opioid prescriptions. By 2016, opioid prescriptions had decreased by 25%, and the number of high-volume prescribers fell by 18%. Additionally, the 2017 guidelines, which limited opioid prescriptions for chronic pain, resulted in a 15% reduction in opioid prescriptions. Furthermore, there was a 40% reduction in opioid prescriptions for acute pain after these guidelines were implemented.

2. Opioid Overdose Data in Maryland

The following table summarizes the opioid overdose data in Maryland over a ten-year period, illustrating the trends in opioid-related deaths, including the growing impact of fentanyl:

Data Point	Value	Source
Opioid-Related Overdose Deaths (2010–2015)	671 deaths in 2011; 1,259 in 2015	Opioid Operational Command Center Review of Demographic Overdose Trends in Maryland by Local Jurisdiction, 2021[14]
Opioid-Related Overdose Deaths (2016–2020)	2,799 deaths in 2020, 222% increase from 2015	Opioid Operational Command Center Review of Demographic Overdose Trends in Maryland by Local Jurisdiction, 2021[14]
Geographical Distribution of Overdose Deaths (2022)	Highest in Baltimore City (989 deaths)	Maryland Department of Health, 2024[15]

Demographic Breakdown of Deaths in 2022 according to Maryland Department of Health, 2024[15]

	<25 years	25-34 years	35-44 years	45-54 years	55+ years
Number of Deaths	126	486	581	549	832
Percentage	4.9%	18.9%	22.6%	21.3%	32.3%

Breakdown of Deaths by Race, 2022 according to Maryland Department of Health, 2024[15]

	White		Black		Hispanic	
	2021	2022	2021	2022	2021	2022
Number of Deaths	1,427	1,297	1,198	1,072	124	152

Breakdown of Deaths by Gender, 2022 according to Maryland Department of Health, 2024[15]

	Male	Female
Number of Deaths	1,830	744

Opioid-related overdose deaths in Maryland showed a significant increase over the past decade. From 671 deaths in 2011, opioid fatalities surged to 1,259 deaths by 2015, representing a 87% increase. This upward trajectory continued, with 2,799 deaths recorded in 2020, marking a 222% increase from 2015. The data suggests that, despite the introduction of regulatory measures such as the Prescription Drug Monitoring Program (PDMP) and stricter opioid prescribing guidelines, these efforts were not sufficient to curb the growing overdose crisis.

The geographical distribution of opioid-related overdose deaths in Maryland shows significant regional disparities. Baltimore City continues to have the highest overdose rates, with 1,005 deaths attributed to opioids in 2016. This reflects the urban concentration of opioid misuse and the significant challenges cities face in addressing addiction and overdose prevention.

In 2022, Maryland's opioid overdose deaths were concentrated in certain age groups. The largest proportion of deaths occurred among individuals aged 55+ years, accounting for 32.3% of all opioid-related fatalities. This was followed by the 35-44 years group, which represented 22.6% of deaths, and the 45-54 years group, which accounted for 21.3%.

In 2022, White individuals accounted for the largest number of opioid-related overdose deaths in Maryland, with 1,297 deaths, followed by Black individuals, who had 1,072 deaths. Hispanic individuals accounted for 152 deaths.

The gender distribution of opioid-related overdose deaths shows that males are disproportionately affected, with 1,830 male deaths in 2022 compared to 744 female deaths.

IV. Discussion

The data collected and presented above demonstrates the intended and unintended effects of Maryland's opioid prescribing policies.

Impact of PDMP and Prescribing Guidelines:

The PDMP and stricter prescribing guidelines have had a clear effect on opioid prescribing practices. Between 2011 and 2016, the state saw a 25% decrease in opioid prescriptions, which was associated with a reduction in high-volume prescribers and misuse behaviours like "doctor shopping." These policies were designed to reduce the availability of prescription opioids, particularly in the context of rising misuse and addiction[15]. However, while prescribing rates have decreased, overdose deaths have not followed the same trend. Opioid-related deaths increased by 115% from 2015 to 2020, indicating that the regulations, while effective in reducing prescription opioids, did not address the broader issues driving the overdose crisis[16].

Geographical and Demographic Disparities:

The analysis also reveals important geographical and demographic trends in the opioid overdose data. Baltimore City saw the highest overdose rates, consistent with the presence of both prescription opioids and illicit substances like fentanyl[15]. Rural areas like Western Maryland, which were previously less affected by the opioid

crisis, have also seen a significant uptick in overdose deaths[17]. These regions, with limited access to healthcare and addiction treatment services, are particularly vulnerable to the proliferation of illicit drugs.

Furthermore, demographic disparities are evident, with Black and Hispanic populations experiencing disproportionately high overdose death rates. Middle-aged adults (35–54), particularly males, have borne the brunt of this epidemic[18].

Maryland's opioid prescribing policies have had a noticeable impact on prescribing practices, but they have not been sufficient to reverse the overall trend in opioid overdose deaths[19]. The introduction of the PDMP and stricter prescribing guidelines have succeeded in reducing the volume of opioid prescriptions, but they have not addressed the increasing role of fentanyl in the overdose crisis[20]. The rising prevalence of fentanyl and other illicit opioids underscores the need for a broader approach that includes better monitoring of illicit drug distribution, enhanced addiction treatment programs, and targeted interventions for at-risk populations[21].

The disparities in overdose death rates across different regions and demographic groups highlight the need for more tailored interventions that take into account socio-economic, geographical, and racial factors. A more comprehensive public health strategy that goes beyond prescription regulation to address the full scope of the opioid epidemic, including the rise of fentanyl and access to treatment, is essential for curbing overdose fatalities in Maryland and other states facing similar challenges.

V. Conclusion

This study has provided valuable insights into the relationship between opioid prescribing practices and overdose rates in Maryland. The analysis of Maryland's opioid prescribing policies, including the implementation of the Prescription Drug Monitoring Program (PDMP) and stricter prescribing guidelines, has revealed a significant reduction in opioid prescriptions over the past decade. However, this decline in prescription opioids has not been accompanied by a proportional decrease in overdose deaths. Geographical and demographic disparities were also evident, with Baltimore City and certain rural areas experiencing the highest overdose rates, and Black and Hispanic populations disproportionately affected.

The findings from Maryland suggest that while opioid prescribing regulations can reduce prescription misuse, they are insufficient to address the broader opioid crisis, particularly with the rise of illicit substances like fentanyl. These results have critical implications for opioid prescribing practices and overdose prevention. At both the state and national levels, there is a pressing need for a more comprehensive approach that combines regulation with enhanced prevention, treatment, and harm reduction strategies.

References

- [1]. Gramlich, J. (2022, January 19). Recent Surge In U.S. Drug Overdose Deaths Has Hit Black Men The Hardest. Pew Research Center. <https://www.pewresearch.org/short-reads/2022/01/19/recent-surge-in-u-s-drug-overdose-deaths-has-hit-black-men-the-hardest/>
- [2]. Brown, D. J. (2023, August 17). State, County Officials Discuss Strategies To Battle The Ever-Changing Opioid Crisis In Maryland - Maryland Matters. Maryland Matters. <https://marylandmatters.org/2023/08/17/state-county-officials-discuss-strategies-to-battle-the-ever-changing-opioid-crisis-in-maryland/>
- [3]. Hogan, L., Rutherford, B., & Schrader, D. (2021). Unintentional Drug-And Alcohol-Related Intoxication Deaths In Maryland, 2020 Maryland Department Of Health. https://health.maryland.gov/vsa/documents/overdose/annual_2020_drug_intox_report.pdf
- [4]. Gherter, R., & Groves, L. (2018, June 28). Economic Opportunity And The Opioid Crisis: Geographic And Economic Trends. <https://aspe.hhs.gov/reports/economic-opportunity-opioid-crisis-geographic-economic-trends>
- [5]. Carrizosa, N., & Latham, K. (2017). Prescription Opioids: Prescriber Education And The Maryland Prescription Drug Monitoring Program. https://www.montgomerycountymd.gov/Olo/Resources/Files/2017%20reports/Olo%20report%202017%2011%20prescription%20opioids.pdf?utm_source=Chatgpt.Com
- [6]. Maryland Department Of Health. (2019). Maryland Department Of Health Recent Updates. Maryland.Gov Enterprise Agency Template. <https://health.maryland.gov/pdmp/pages/pdmp-updates.aspx>
- [7]. Jones, M. R., Viswanath, O., Peck, J., Kaye, A. D., Gill, J. S., & Simopoulos, T. T. (2018). A Brief History Of The Opioid Epidemic And Strategies For Pain Medicine. *Pain And Therapy*, 7(1), 13–21. National Library Of Medicine. <https://doi.org/10.1007/S40122-018-0097-6>
- [8]. Centers For Disease Control And Prevention. (2024, November 1). Understanding The Opioid Overdose Epidemic. Overdose Prevention. <https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html>
- [9]. Chihuri, S., Fink, D. S., Cerdá, M., Keyes, K. M., & Li, G. (2020). Prescription Drug Monitoring Programs And Prescription Opioid-Related Outcomes In The United States. *Epidemiologic Reviews*, 42(1). <https://doi.org/10.1093/epirev/mxaa002>
- [10]. Alvaro, C.-C., Ponicki, W. R., Gaidus, A., Gruenewald, P. J., Marshall, B. D. L., Fink, D. S., Martins, S. S., Rivera-Aguirre, A., Wintemute, G. J., & Cerdá, M. (2019). Prescription Drug Monitoring Programs And Opioid Overdoses. *Epidemiology*, 30(2), 212–220. <https://doi.org/10.1097/Ede.0000000000000950>
- [11]. State Of Maryland - Dhmh. (2017). 2016 Annual Report. In <https://health.maryland.gov/pdmp/documents/annual%20report/2016%20annual%20report.pdf#search=prescription%20drug%20monitoring%20program%202016%20annual%20report>
- [12]. Cdc. (2024, November 7). Opioid Dispensing Rate Maps. Overdose Prevention. https://www.cdc.gov/overdose-prevention/data-research/facts-stats/opioid-dispensing-rate-maps.html#Cdc_Data_Surveillance_Section_2-State-Opioid-Dispensing-Rates
- [13]. State Of Maryland - Dhmh. (2017). 2016 Annual Report. In [https://health.maryland.gov/bha/documents/health-general%20C2%A7%2021-2a-05\(F\)3%20-%20bha%20Annual%20prescription%20drug%20monitoring%20program%20report.pdf#search=prescription%20drug%20monitoring%20program](https://health.maryland.gov/bha/documents/health-general%20C2%A7%2021-2a-05(F)3%20-%20bha%20Annual%20prescription%20drug%20monitoring%20program%20report.pdf#search=prescription%20drug%20monitoring%20program)

- [14]. Baltimore. (2016). Maryland's Health Department Releases 2016 Fatal Overdose Data. Legistorm.Com. https://www.legistorm.com/stormfeed/view_rss/2646863/organization/79739/title/Marylandas-Health-Department-Releases-2016-Fatal-Overdose-Data.html
- [15]. Maryland Department Of Health. (2024, August). Unintentional Drug- And Alcohol-Related Intoxication Deaths In Maryland, 2022. Health.Maryland.Gov. https://health.maryland.gov/vsa/documents/overdose/2022_annualintoxdeathreport.pdf
- [16]. Congressional Research Service. (2022). The Opioid Crisis In The United States: A Brief History. Congressional Research Service. <https://crsreports.congress.gov/product/pdf/IF/IF12260>
- [17]. Alexander, R. T., Hedrick, C. W., Alexander, S. D., & Fowler, D. R. (2016). Epidemic Fentanyl Deaths In Maryland: A Public Health Intervention Involving Geographic Information Systems And Collaboration With The Drug Enforcement Administration. *Academic Forensic Pathology*, 6(2), 301–314. <https://doi.org/10.23907/2016.031>
- [18]. Harris, R. A. (2022). Drug Overdose Deaths Among Non-Hispanic Black Men In The Us: Age-Specific Projections Through 2025. *Ajpm Focus*, 2(1), 100063. <https://doi.org/10.1016/J.Focus.2022.100063>
- [19]. Phillips, J. K., Ford, M. A., & Bonnie, R. J. (2017, July 13). Evidence On Strategies For Addressing The Opioid Epidemic. Nih.Gov; National Academies Press (Us). <https://www.ncbi.nlm.nih.gov/books/Nbk458653/>
- [20]. Dowell, D., Ragan, K., Jones, C., Baldwin, G., & Chou, R. (2022). Cdc Clinical Practice Guideline For Prescribing Opioids For Pain — United States, 2022. *Mmwr. Recommendations And Reports*, 71(3), 1–95. <https://doi.org/10.15585/mmwr.Rr7103a1>
- [21]. Han, Y., Yan, W., Zheng, Y., Khan, M. Z., Yuan, K., & Lu, L. (2019). The Rising Crisis Of Illicit Fentanyl Use, Overdose, And Potential Therapeutic Strategies. *Translational Psychiatry*, 9(1). <https://doi.org/10.1038/S41398-019-0625-0>